December 12, 2019 09:30 AM Eastern Standard Time CAMBRIDGE, Mass. (BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc., today announced the appointment of Debra Canner as the company’s first Global Head of Human Resources. Deb will serve on Amylyx’ Executive Team, overseeing the company’s human resource efforts, including talent management, organizational leadership, culture and corporate responsibility. “Becoming part of [...]
Amylyx Pharmaceuticals Announces Last Patient Completes Last Study Visit in CENTAUR Phase 2 Study of AMX0035 in ALS
October 04, 2019 12:50 PM Eastern Daylight Time CAMBRIDGE, Mass. (BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, today announced that the last participant has completed the planned 24 weeks of study treatment in CENTAUR, a clinical trial assessing the safety and [...]
Amylyx Pharmaceuticals Strengthens Leadership Team with the Appointments of Chief Medical Officer, Chief Commercial Officer and Global Head, Supply Chain
June 24, 2019 10:46 AM Eastern Daylight Time CAMBRIDGE, MA (BUSINESS WIRE) — Amylyx Pharmaceuticals, Inc., today announced three additions to its executive leadership team, appointing industry veterans Patrick Yeramian, M.D., MBA, as chief medical officer, Margaret Olinger, MBA, as chief commercial officer and Tom Holmes as global head, supply chain. These three key appointments serve [...]
Amylyx Pharmaceuticals Announces First Patients Dosed in PEGASUS Phase 2 Trial of AMX0035 in Alzheimer’s Disease and Expansion of the Trial
April 03, 2019 08:30 AM Eastern Daylight Time CAMBRIDGE, MA (BUSINESS WIRE) — Amylyx Pharmaceuticals, Inc., in collaboration with the Alzheimer’s Association, the Alzheimer’s Drug Discovery Foundation (ADDF) and the Cure Alzheimer’s Fund, today announced the dosing of its first patients in a recently expanded Phase 2 clinical trial (PEGASUS) to assess AMX0035 in individuals with Alzheimer’s [...]
The Alzheimer’s Association and Alzheimer’s Drug Discovery Foundation (ADDF) are collaborating to jointly fund a new combination therapy clinical trial for Alzheimer’s disease to be conducted by Amylyx Pharmaceuticals. The $1.85 million grant is the first award under an initiative created by the Alzheimer’s Association and the ADDF to fund combination therapies.
Amylyx Pharmaceuticals Receives FDA Orphan Drug Designation for AMX0035 for the Treatment of Amyotrophic Lateral Sclerosis
Amylyx Pharmaceuticals, Inc., announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to AMX0035, an oral therapeutic in clinical development for the treatment of amyotrophic lateral sclerosis (ALS). The Company recently began a Phase 2 clinical study, the CENTAUR trial, to evaluate the safety and efficacy of AMX0035 in ALS patients.
Project ALS and Amylyx Pharmaceuticals today announced a collaboration to undertake pre-clinical studies with Amylyx’s oral compound AMX0035 to advance the understanding of the compound’s neurobiological effects. The studies to be conducted at the Project ALS Pre-Clinical Core at Columbia University’s Motor Neuron Center will complement the company’s recently initiated Phase 2 clinical program of AMX0035 for the treatment of amyotrophic lateral sclerosis (ALS).